Developer docs
API playgroundTry for free, no card

Search company profiles

OssDsign

Full company profile

uuid0004la9

Namestring
OssDsign
Legal namestring
OssDsign AB (publ)
Websiteurl
ossdsign.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

OssDsign AB (publ) is a Sweden-based, Nasdaq First North–listed orthobiologics company that develops, manufactures, and commercializes the OssDsign Catalyst bone graft substitute — a nanosynthetic, silicate-substituted calcium phosphate designed to upregulate cellular BMP-2, drive dual-pathway (endochondral and intramembranous) healing, and undergo cell-mediated coupled remodeling. The company is the product of a 2011 Uppsala University / Karolinska University spinout, an orthopedic pivot enabled by the November 2020 acquisition of SIRAKOSS Ltd, and a January 2024 strategic restructuring that discontinued the legacy cranial implant business to make Catalyst the sole commercial focus.

The company's commercial product, OssDsign Catalyst, is sold in 1cc–10cc putty volumes for spinal fusion (including ACDF, posterior, deformity, posterolateral, and interbody applications across cervical, thoracic, and lumbar), as well as pelvic (sacroiliac, hip revision), extremity, and trauma indications. Catalyst became the first synthetic bone graft to receive FDA clearance for spinal interbody fusions based on bone graft data alone, with supporting clinical evidence including a 93% fusion rate in the TOP FUSION first-in-human study and 88.4% fusion in the real-world PROPEL registry's complex-patient cohort.

OssDsign generates revenue entirely through B2B hardware sales of Catalyst to hospitals, surgical centers, and surgeons, primarily in the United States through a direct sales force that the company intends to double by 2026, complemented by Integrated Delivery Network (IDN) agreements that provide network-wide access with pre-negotiated pricing. The company reported FY2025 revenue of SEK 180.2 million (~45% growth at constant FX) at a 96.3% gross margin, while remaining EBITDA-negative as it invests in U.S. commercial expansion, clinical programs, and production scaling — funded in part by directed share issues of SEK 150M (September 2023) and SEK 158M (June 2025).

Short descriptiontext

OssDsign is a Sweden-based orthobiologics company that develops and sells OssDsign Catalyst, a nanosynthetic silicate-substituted bone graft for spinal fusion and orthopedic procedures, primarily to U.S. hospitals and surgeons through a direct sales force and IDN agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUppsala, Sweden
HQ citystring
Uppsala
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orthobiologics products, bone graft substitutes, spinal fusion implants, nanosynthetic bone grafts, medical device manufacturing
Industry4 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAC
Spine Implants & Motion Preservation (Fusion/Disc/Interspinous)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAA
Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Orthobiologics and Bone Graft Substitutes
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1OssDsign Catalyst Bone Graft Sales
TypeHardware Sales
Description

Sale of nanosynthetic bone graft products to hospitals, surgical centers, and surgeons. Revenue generated from product sales in spinal fusion, extremity, pelvis, and trauma applications. The company has shown strong growth with 45% annual revenue growth and high gross margins of 96.3%.

news.cision.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1OssDsign Catalyst
Description

Nanosynthetic, silicate-substituted bone graft designed to upregulate cellular BMP-2, drive dual-pathway healing, and cell-mediated coupled remodeling for rapid, robust fusion in spine and other orthopedic applications

ossdsign.com
+2 more records
Core offering1 text field

OssDsign develops and commercializes OssDsign Catalyst, a nanosynthetic, silicate-substituted bone graft substitute cleared by the FDA for spinal interbody fusions and orthopedic applications. The product is sold in putty form (1cc, 2.5cc, 5cc, 10cc) to hospitals and surgeons, primarily in the U.S. market, for use in spinal fusion (cervical, thoracic, lumbar), sacroiliac fusion, extremities, and trauma indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 93% fusion rate within 12 months in complex multi-level spinal surgeries
+5 more records
Product overview1 text field

OssDsign is a developer and global provider of next generation orthobiologics products. The company operates as a pure play orthobiologics company following a strategic shift in September 2023, focusing solely on its OssDsign Catalyst platform. OssDsign Catalyst is a nanosynthetic, silicate-substituted bone graft substitute that supports the body's own healing capabilities. The product is indicated for use in multiple applications including spinal fusion procedures (cervical, thoracic, lumbar), pelvic procedures (sacroiliac fusion, hip revision), extremities (foot & ankle, hand & wrist), and trauma (fractures, non-unions). It was the first synthetic bone graft to receive clearance for use in spinal interbody fusions based on bone graft data alone.

Product and service1 record
1OssDsign Catalyst
CategoryOrthobiologics / Bone Graft Substitute
Description

A nanosynthetic, silicate-substituted bone graft substitute designed to upregulate cellular BMP-2, drive dual-pathway healing (endochondral + intramembranous ossification), and enable cell-mediated coupled remodeling for rapid, robust fusion. Available in putty form in 1cc, 2.5cc, 5cc, and 10cc sizes. Indicated for spinal fusion (cervical, thoracic, lumbar, including ACDF, posterior fusion, deformity correction, posterolateral fusion, interbody fusion), sacroiliac fusion, hip revision, foot & ankle, hand & wrist, and trauma (fractures, non-unions). Sold to hospitals, surgical centers, and spine/orthopedic surgeons via direct sales force. First synthetic bone graft cleared by FDA for spinal interbody fusions based on bone graft data alone.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthers
Description

Re-elected as company auditor at 2026 AGM. Provides audit services per Swedish Companies Act requirements.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest spine and orthopedic device company with the Infuse Bone Graft (rhBMP-2) product, the dominant alternative to OssDsign Catalyst in spinal fusion. Directly comparable because it competes for the same spine surgeon customer, the same IDN formulary decision, and the same procedure indications.

TypeBroad incumbent
Description

Major spine and orthopedic franchise offering bone graft and biologic solutions alongside extensive hardware portfolios. Comparable as an incumbent competing for the same spine surgeon adoption and IDN contracts in spinal fusion.

TypeDirect peer
Description

Spine-focused pure-play with significant orthobiologics offerings following the NuVasive merger. Comparable as a direct competitor in spinal fusion procedures, including bone graft substitutes, targeting the same spine surgeons and hospitals.

TypeBroad incumbent
Description

Global orthopedics and spine incumbent with a broad portfolio including bone graft substitutes, demineralized bone matrix products, and biologics. Comparable as a competing orthobiologics and spine hardware supplier targeting the same hospital and IDN customers.

TypeDirect peer
Description

Spine-focused pure-play acquired by Integra LifeSciences, with a portfolio including bone graft substitutes and orthobiologics (OsteoStrand, OsteoSurge). Comparable as a spinal fusion-focused orthobiologics competitor with a similar surgeon and IDN customer profile.

TypeDirect peer
Description

Commercial-stage orthobiologics company with i-FACTOR peptide-enhanced bone graft, the first PMA-approved bone graft for cervical spine. Comparable as a focused orthobiologics player competing in spinal fusion with a differentiated biologic/synthetic bone graft.

TypeDirect peer
Description

Pure-play orthobiologics company marketing CERAMENT, a synthetic injectable bone graft substitute. Highly comparable as a similarly sized European-headquartered pure-play orthobiologics competitor with synthetic bone graft technology for trauma, foot/ankle, and spine-adjacent indications.

TypeBroad incumbent
Description

Spine and orthopedic device company with a dedicated biologics portfolio (including Trinity ELITE and FiberFuse) and trauma fixation. Comparable as a competing orthobiologics supplier and adjacent spine/trauma hardware player; Adam McCollister's prior experience at Orthofix reinforces the commercial comparability.

TypeDirect peer
Description

Pure-play orthobiologics company offering a portfolio of bone graft substitutes and fixation devices for spine and orthopedic surgery. Comparable as a similarly sized orthobiologics-focused public peer competing in the same hospital channel.

TypeBroad incumbent
Description

Major spine surgery specialist with proprietary orthobiologics offerings (Osteocel, AttraX). Comparable as a spine-focused competitor in the same bone graft substitute category, with strong surgeon relationships in spinal fusion procedures.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OssDsign

Orthobiologics and Bone Graft Substitutesossdsign.com

OssDsign is a Sweden-based orthobiologics company that develops and sells OssDsign Catalyst, a nanosynthetic silicate-substituted bone graft for spinal fusion and orthopedic procedures, primarily to U.S. hospitals and surgeons through a direct sales force and IDN agreements.

What OssDsign does

OssDsign AB (publ) is a Sweden-based, Nasdaq First North–listed orthobiologics company that develops, manufactures, and commercializes the OssDsign Catalyst bone graft substitute — a nanosynthetic, silicate-substituted calcium phosphate designed to upregulate cellular BMP-2, drive dual-pathway (endochondral and intramembranous) healing, and undergo cell-mediated coupled remodeling. The company is the product of a 2011 Uppsala University / Karolinska University spinout, an orthopedic pivot enabled by the November 2020 acquisition of SIRAKOSS Ltd, and a January 2024 strategic restructuring that discontinued the legacy cranial implant business to make Catalyst the sole commercial focus.

The company's commercial product, OssDsign Catalyst, is sold in 1cc–10cc putty volumes for spinal fusion (including ACDF, posterior, deformity, posterolateral, and interbody applications across cervical, thoracic, and lumbar), as well as pelvic (sacroiliac, hip revision), extremity, and trauma indications. Catalyst became the first synthetic bone graft to receive FDA clearance for spinal interbody fusions based on bone graft data alone, with supporting clinical evidence including a 93% fusion rate in the TOP FUSION first-in-human study and 88.4% fusion in the real-world PROPEL registry's complex-patient cohort.

OssDsign generates revenue entirely through B2B hardware sales of Catalyst to hospitals, surgical centers, and surgeons, primarily in the United States through a direct sales force that the company intends to double by 2026, complemented by Integrated Delivery Network (IDN) agreements that provide network-wide access with pre-negotiated pricing. The company reported FY2025 revenue of SEK 180.2 million (~45% growth at constant FX) at a 96.3% gross margin, while remaining EBITDA-negative as it invests in U.S. commercial expansion, clinical programs, and production scaling — funded in part by directed share issues of SEK 150M (September 2023) and SEK 158M (June 2025).

OssDsign firmographics

Firmographics
Name
OssDsign
Legal name
OssDsign AB (publ)
Website
https://ossdsign.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
OssDsign is a Sweden-based orthobiologics company that develops and sells OssDsign Catalyst, a nanosynthetic silicate-substituted bone graft for spinal fusion and orthopedic procedures, primarily to U.S. hospitals and surgeons through a direct sales force and IDN agreements.
Ownership category
akta.pro rank

OssDsign industry classification

Industry
Product category
Orthobiologics and Bone Graft Substitutes
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAC
Spine Implants & Motion Preservation (Fusion/Disc/Interspinous)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAA
Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Orthobiologics products
  • Bone graft substitutes
  • Spinal fusion implants
  • Nanosynthetic bone grafts
  • Medical device manufacturing

Where OssDsign is headquartered

Location

Headquarters

HQ city
Uppsala
HQ country
Sweden
HQ region
Europe

Offices3 records

Markets served

OssDsign business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain

Revenue model

  1. OssDsign Catalyst Bone Graft Sales: Sale of nanosynthetic bone graft products to hospitals, surgical centers, and surgeons. Revenue generated from product sales in spinal fusion, extremity, pelvis, and trauma applications. The company has shown strong growth with 45% annual revenue growth and high gross margins of 96.3%.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

OssDsign product offering

Product offering

Core offering

OssDsign develops and commercializes OssDsign Catalyst, a nanosynthetic, silicate-substituted bone graft substitute cleared by the FDA for spinal interbody fusions and orthopedic applications. The product is sold in putty form (1cc, 2.5cc, 5cc, 10cc) to hospitals and surgeons, primarily in the U.S. market, for use in spinal fusion (cervical, thoracic, lumbar), sacroiliac fusion, extremities, and trauma indications.

Product overview

OssDsign is a developer and global provider of next generation orthobiologics products. The company operates as a pure play orthobiologics company following a strategic shift in September 2023, focusing solely on its OssDsign Catalyst platform. OssDsign Catalyst is a nanosynthetic, silicate-substituted bone graft substitute that supports the body's own healing capabilities. The product is indicated for use in multiple applications including spinal fusion procedures (cervical, thoracic, lumbar), pelvic procedures (sacroiliac fusion, hip revision), extremities (foot & ankle, hand & wrist), and trauma (fractures, non-unions). It was the first synthetic bone graft to receive clearance for use in spinal interbody fusions based on bone graft data alone.

Differentiator

Problem solved

Functional benefit

Brands

  • OssDsign Catalyst: Nanosynthetic, silicate-substituted bone graft designed to upregulate cellular BMP-2, drive dual-pathway healing, and cell-mediated coupled remodeling for rapid, robust fusion in spine and other orthopedic applications
  • PROPEL Spine Registry
  • TOP FUSION

Products and services

  • OssDsign Catalyst A nanosynthetic, silicate-substituted bone graft substitute designed to upregulate cellular BMP-2, drive dual-pathway healing (endochondral + intramembranous ossification), and enable cell-mediated coupled remodeling for rapid, robust fusion. Available in putty form in 1cc, 2.5cc, 5cc, and 10cc sizes. Indicated for spinal fusion (cervical, thoracic, lumbar, including ACDF, posterior fusion, deformity correction, posterolateral fusion, interbody fusion), sacroiliac fusion, hip revision, foot & ankle, hand & wrist, and trauma (fractures, non-unions). Sold to hospitals, surgical centers, and spine/orthopedic surgeons via direct sales force. First synthetic bone graft cleared by FDA for spinal interbody fusions based on bone graft data alone.

Quantifiable outcome

  • 93% fusion rate within 12 months in complex multi-level spinal surgeries
  • +5 more outcomes

Companies that use OssDsign

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

OssDsign technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

OssDsign partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ernst & Young ABminorOthersRe-elected as company auditor at 2026 AGM. Provides audit services per Swedish Companies Act requirements.

Scale indicators10 records

Recent moves9 records

Expansion highlights5 records

OssDsign competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Largest spine and orthopedic device company with the Infuse Bone Graft (rhBMP-2) product, the dominant alternative to OssDsign Catalyst in spinal fusion. Directly comparable because it competes for the same spine surgeon customer, the same IDN formulary decision, and the same procedure indications.
  • DePuy Synthes (Johnson & Johnson MedTech): Major spine and orthopedic franchise offering bone graft and biologic solutions alongside extensive hardware portfolios. Comparable as an incumbent competing for the same spine surgeon adoption and IDN contracts in spinal fusion.
  • Stryker: Global orthopedics and spine incumbent with a broad portfolio including bone graft substitutes, demineralized bone matrix products, and biologics. Comparable as a competing orthobiologics and spine hardware supplier targeting the same hospital and IDN customers.
  • Orthofix Medical: Spine and orthopedic device company with a dedicated biologics portfolio (including Trinity ELITE and FiberFuse) and trauma fixation. Comparable as a competing orthobiologics supplier and adjacent spine/trauma hardware player; Adam McCollister's prior experience at Orthofix reinforces the commercial comparability.
  • NuVasive (legacy entity, now part of Globus Medical): Major spine surgery specialist with proprietary orthobiologics offerings (Osteocel, AttraX). Comparable as a spine-focused competitor in the same bone graft substitute category, with strong surgeon relationships in spinal fusion procedures.

Direct peers

  • Globus Medical: Spine-focused pure-play with significant orthobiologics offerings following the NuVasive merger. Comparable as a direct competitor in spinal fusion procedures, including bone graft substitutes, targeting the same spine surgeons and hospitals.
  • SeaSpine: Spine-focused pure-play acquired by Integra LifeSciences, with a portfolio including bone graft substitutes and orthobiologics (OsteoStrand, OsteoSurge). Comparable as a spinal fusion-focused orthobiologics competitor with a similar surgeon and IDN customer profile.
  • Cerapedics: Commercial-stage orthobiologics company with i-FACTOR peptide-enhanced bone graft, the first PMA-approved bone graft for cervical spine. Comparable as a focused orthobiologics player competing in spinal fusion with a differentiated biologic/synthetic bone graft.
  • BONESUPPORT: Pure-play orthobiologics company marketing CERAMENT, a synthetic injectable bone graft substitute. Highly comparable as a similarly sized European-headquartered pure-play orthobiologics competitor with synthetic bone graft technology for trauma, foot/ankle, and spine-adjacent indications.
  • Xtant Medical: Pure-play orthobiologics company offering a portfolio of bone graft substitutes and fixation devices for spine and orthopedic surgery. Comparable as a similarly sized orthobiologics-focused public peer competing in the same hospital channel.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

OssDsign social profiles

Digital presence

OssDsign financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OssDsign leadership team

Management profile

Number of profiles

Profiles7 records

OssDsign funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OssDsign M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OssDsign

What does OssDsign do?

OssDsign develops and commercializes OssDsign Catalyst, a nanosynthetic, silicate-substituted bone graft substitute cleared by the FDA for spinal interbody fusions and orthopedic applications. The product is sold in putty form (1cc, 2.5cc, 5cc, 10cc) to hospitals and surgeons, primarily in the U.S. market, for use in spinal fusion (cervical, thoracic, lumbar), sacroiliac fusion, extremities, and trauma indications.

Is OssDsign a public or private company?

OssDsign is a public company. It is classified as public and is currently operating.

When was OssDsign founded?

OssDsign was founded in 2011. It employs 11 to 50 people.

Where is OssDsign based?

OssDsign is headquartered in Uppsala, Sweden, in the Europe region.

How does OssDsign make money?

One revenue line is on record: ossDsign Catalyst Bone Graft Sales.

Who are OssDsign's main competitors?

Broad incumbents on record are Medtronic, DePuy Synthes (Johnson & Johnson MedTech), Stryker, Orthofix Medical and NuVasive (legacy entity, now part of Globus Medical). Direct peers are Globus Medical, SeaSpine, Cerapedics, BONESUPPORT and Xtant Medical.

Does OssDsign have an API?

No public API is recorded for OssDsign.

What industry is OssDsign in?

OssDsign's product category is Orthobiologics and Bone Graft Substitutes. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAHAEAC, Spine Implants & Motion Preservation (Fusion/Disc/Interspinous). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comEarnings call transcript: OssDsign Q3 2026 sales fall as stock slips near lowOssDsign reported Q3 2026 sales fell 18.8% year-over-year to SEK 35.7 million, while gross margin improved to 93.2%. The company attributed the decline to seasonal softness and a larger-than-expected sales reorganization, and shares dropped 5.45% to $3.30.news.cision.comOssDsign surpasses 400 patients in PROPEL spine registry evaluating OssDsign Catalyst®OssDsign announced that over 400 patients have been enrolled in the PROPEL spine registry evaluating its OssDsign Catalyst bone graft. The registry previously reported an 88.4% fusion rate at 12 months among 108 patients, with no unexpected adverse events. The company highlighted the milestone as a major achievement compared to other biologics and synthetics.AffarsvarldenOssdsign ökar förlust – minskar omsättningOssdsign reported an 18.7% decline in second-quarter revenue to 37.8 million SEK, accompanied by a widened operating loss of 12.3 million SEK compared to the previous year's period. CEO Mark Waugh attributed the results to seasonal effects in the US market but expressed confidence that ongoing efforts to strengthen the company's fundamentals will lead to growth later this year.Dagens industriÖkade förluster för medicinteknikbolagetMedical technology company Ossdsign reported an adjusted operating loss of 12.0 million kronor for the second quarter of 2026, marking a significant increase from the 6.2 million kronor loss in the same period last year. The company, which specializes in implants for cranial reconstruction, saw its financial deficit nearly double compared to the previous year.news.cision.comOssDsign AB (publ) publishes Q2 2026 interim reportOssDsign AB published its Q2 2026 interim report, showing net sales of TSEK 37,776, flat quarter-over-quarter, and adjusted EBIT of TSEK -11,975. Gross margin improved to 92.1% from 91.6% in Q1, but remained below the prior year's 96.8% due to product and customer mix. The company also reported a catalyst study outperforming earlier-generation bone graft.news.cision.comOssDsign appoints Adam McCollister as new Vice President of SalesOssDsign appointed Adam McCollister as Vice President of Sales to lead U.S. sales strategy for its Catalyst nanosynthetic bone graft. McCollister previously served as Regional VP at Treace Medical Concepts and held sales roles with Stryker and Tornier. He will focus on accelerating adoption of Catalyst in the U.S. market.news.cision.comAnnual General Meeting held in OssDsign ABOssDsign AB held its 2026 annual general meeting on 9 June 2026, adopting the 2025 financial statements and granting board discharge. The company decided no dividend for 2025, set board fees at SEK 1,300,000, and approved a warrant program for up to 3,100,000 warrants.news.cision.comOssDsign Catalyst® outperforms earlier-generation bone graft as a standalone treatment in trauma studyA preclinical study in The Journal of Bone and Mineral Research compared OssDsign Catalyst to an earlier-generation bone graft in rabbit knee defects. OssDsign Catalyst achieved full healing at 4 weeks, while the earlier graft took twice as long, and its material decreased by 60% over 26 weeks. The results support the superiority of fourth-generation synthetic bone grafts.news.cision.comOssDsign AB announces updated proposal regarding board fees ahead of the annual general meeting 2026OssDsign AB's nomination committee updated its board fee proposal ahead of the 9 June 2026 annual general meeting, adding audit committee fees. The total board fees remain SEK 1,300,000, with SEK 120,000 added for audit committee members, including SEK 80,000 to the chairman.openPR.comCranial And Facial Implants Market Size to Reach USD 2,030.42 million by 2032Credence Research released a market report projecting the global cranial and facial implants market to grow from USD 1,372.85 million in 2025 to USD 2,030.42 million by 2032, representing a compound annual growth rate of 6.74%. The report identifies key growth drivers including rising demand for reconstructive surgeries, increasing preference for patient-specific implants, and technological advancements in 3D printing and digital surgical planning. Major companies operating in this market include Stryker, Zimmer Biomet, DePuy Synthes, Medtronic, KLS Martin, Integra LifeSciences, B. Braun, OssDsign, Renishaw, and Acumed.